177Lu-SN201
Spago takes Tumorad-01 study to the next level
Spago Nanomedical has increased the dose of its cancer drug candidate 177Lu-SN201 in its phase I/IIa Tumorad-01 study, following...
Spago’s CEO: “We want to expand cancer treatment with effective radiopharmaceuticals”
2024 has marked a defining chapter for Spago...
Spago’s phase I/IIa cancer trial progressing steadily
The positive momentum for Spago Nanomedical carries over...
First patient dosed in Spago’s phase I/IIa trial
Spago Nanomedical recently received approval to start the...
Spago Nanomedical’s SAB on Tumorad’s potential
Recently, Spago Nanomedical announced that the company has...
Spago Nanomedicals CDO om studieansökan
Spago Nanomedical lämnade nyligen in ansökan om att...
Tumorad clinical start around the corner for Spago Nanomedical
Encouraged by positive preclinical data with Tumorad, Spago...
Spago Nanomedical redovisar avancemang
ACS Omega
Spago Nanomedical publicerar positiva prekliniska data
Prekliniska data med Spago Nanomedicals radionuklidkoncept Tumorad har...
Spago Nanomedical startar fas IIa-studie i endometrios
Lundabaserade Spago Nanomedical meddelade nyligen att bolaget fått...
Spago Nanomedical i hett område
Radionuklidterapier mot cancer är ett hett område som...
Spago Nanomedical om höstens nyhetsflöde
Under andra kvartalet genomförde Lundabolaget Spago Nanomedical en...
